Product nameAnti-AACT antibody [EPR5905]
See all AACT primary antibodies
DescriptionRabbit monoclonal [EPR5905] to AACT
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P
Species reactivityReacts with: Human
Recombinant fragment within Human AACT aa 250-450. The exact sequence is proprietary.
- WB: Human plasma and colon cancer lysates.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.5% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab129194 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Detects a band of approximately 68 kDa (predicted molecular weight: 47 kDa).|
|IP||1/10 - 1/100.|
FunctionAlthough its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.
Tissue specificityPlasma. Synthesized in the liver. Like the related alpha-1-antitrypsin, its concentration increases in the acute phase of inflammation or infection. Found in the amyloid plaques from the hippocampus of Alzheimer disease brains.
Involvement in diseaseDefects in SERPINA3 may be a cause of chronic obstructive pulmonary disease (COPD) [MIM:107280].
Sequence similaritiesBelongs to the serpin family.
DomainThe reactive center loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site within the RCL, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.
- Information by UniProt
- SERPINA3 antibody
- AACT antibody
- AACT_HUMAN antibody
ab129194 has been referenced in 1 publication.
- Valko PO et al. In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. J Sleep Res N/A:e12721 (2018). PubMed: 29961995